| Q47558004 | A Retrospective Assessment of Four Antigen Assays for the Detection of Invasive Candidiasis Among High-Risk Hospitalized Patients. |
| Q89763709 | A proposal for a comprehensive approach to infections across the surgical pathway |
| Q36290663 | Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy. |
| Q38082740 | Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections |
| Q38165883 | An Italian consensus for invasive candidiasis management (ITALIC). |
| Q24186457 | Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients |
| Q49425859 | Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis |
| Q36125981 | Application of Mass Spectrometry Technology to Early Diagnosis of Invasive Fungal Infections |
| Q90308249 | Applying the Host-Microbe Damage Response Framework to Candida Pathogenesis: Current and Prospective Strategies to Reduce Damage |
| Q37551817 | Appropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation? |
| Q91992315 | Biomarker-guided antifungal stewardship policies for patients with invasive candidiasis |
| Q38694666 | Bloodstream infections in internal medicine. |
| Q64073590 | Can presepsin be used for screening invasive fungal infections? |
| Q38130314 | Candida albicans, plasticity and pathogenesis |
| Q41299438 | Candida biomarkers in patients with candidaemia and bacteraemia |
| Q55460853 | Candida-Reactive T Cells for the Diagnosis of Invasive Candida Infection—A Prospective Pilot Study. |
| Q59328995 | Cell wall mannan of Candida krusei mediates dendritic cell apoptosis and orchestrates Th17 polarization via TLR-2/MyD88-dependent pathway |
| Q38220697 | Characteristic and clinical relevance of Candida mannan test in the diagnosis of probable invasive candidiasis |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q38067507 | Combined use of nonculture-based lab techniques in the diagnosis and management of critically ill patients with invasive fungal infections |
| Q36884375 | Comparison of (1->3)-β-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia |
| Q38284461 | Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. |
| Q36902916 | Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions |
| Q40454880 | Current Algorithms in Fungal Diagnosis in the Immunocompromised Host. |
| Q38531765 | Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis |
| Q87789600 | Diagnosing Invasive Candidiasis |
| Q26745677 | Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy |
| Q35678921 | Diagnosis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-2) |
| Q40524695 | Diagnosis of invasive fungal diseases in pediatric patients |
| Q37939026 | Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). |
| Q64056255 | Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis |
| Q90164293 | Diagnostic Performance of a Novel Multiplex PCR Assay for Candidemia among ICU Patients |
| Q34750701 | Diagnostic value of immunoglobulin G antibodies against Candida enolase and fructose-bisphosphate aldolase for candidemia |
| Q37934487 | ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients |
| Q37974519 | ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia |
| Q26852351 | Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients |
| Q91691372 | Endobronchial fungal infection caused by Candida albicans with main bronchus obstruction: a case report |
| Q35977947 | Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients |
| Q39515812 | Evaluation of multiplex PCR in first episodes of febrile neutropenia as a tool to improve early yeast diagnosis in leukemic/preleukemic patients |
| Q40948260 | Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. |
| Q40266645 | Evaluation of the (1,3)-β-D-glucan assay for the diagnosis of neonatal invasive yeast infections. |
| Q37699716 | Factors predicting prolonged empirical antifungal treatment in critically ill patients |
| Q38073717 | Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care |
| Q62241543 | Fungal infection in solid organ recipients |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q35568846 | How to treat fungal infections in ICU patients |
| Q35457899 | How to treat severe infections in critically ill neutropenic patients? |
| Q38215670 | Identification and management of invasive mycoses in internal medicine: a road-map for physicians |
| Q38912624 | Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples. |
| Q41114356 | IgG1 anti-cell wall and IgG2 anti-phosphopeptidomannan antibodies in the diagnosis of invasive candidiasis and heavy Candida colonization. |
| Q58091190 | Increased presepsin levels are associated with the severity of fungal bloodstream infections |
| Q30235457 | Intensive care medicine research agenda on invasive fungal infection in critically ill patients |
| Q89395812 | Invasive Candida Infections in the ICU: Diagnosis and Therapy |
| Q40621471 | Invasive Esophageal Candidiasis with Chronic Mediastinal Abscess and Fatal Pneumomediastinum. |
| Q56040929 | Invasive candidiasis |
| Q22305429 | Invasive candidiasis as a cause of sepsis in the critically ill patient |
| Q35010671 | Invasive candidiasis in non-hematological patients |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q40454846 | Isolation of Nucleic Acids for Fungal Diagnosis. |
| Q35122093 | Management of invasive candidiasis in nonneutropenic ICU patients |
| Q59412778 | Mannose-Binding Lectin Levels and Variation During Invasive Candidiasis |
| Q33958612 | Mannosylation in Candida albicans: role in cell wall function and immune recognition. |
| Q37987555 | New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. |
| Q49803837 | Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences |
| Q38266817 | Non-cultural methods for the diagnosis of invasive fungal disease |
| Q38589279 | Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis |
| Q38061190 | Occurrence, presentation and treatment of candidemia |
| Q90066081 | Pooled analysis of T2 Candida for rapid diagnosis of candidiasis |
| Q35100021 | Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. |
| Q39416559 | Progress in the Diagnosis of Invasive Fungal Disease in Children. |
| Q28077381 | Recent developments in the management of invasive fungal infections in patients with oncohematological diseases |
| Q41996456 | Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children |
| Q64264315 | Severe Cutaneous Candidiasis in a Liver Transplant Patient |
| Q38979163 | Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection |
| Q55437393 | T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications. |
| Q59294372 | The State-of-the-Art Mycology Laboratory: Visions of the Future |
| Q26861652 | The epidemiology and diagnosis of invasive candidiasis among premature infants |
| Q58772447 | Treatment of Invasive Candidiasis: A Narrative Review |
| Q46752133 | Treatment of invasive candidiasis: between guidelines and daily clinical practice |
| Q43707773 | Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies |
| Q47749829 | What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. |
| Q38203447 | What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients |
| Q26825753 | β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3) |